• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国诊断程序研究的一种新方法。

A new approach to the study of diagnostic procedures in the United States.

作者信息

Henkin R E

机构信息

Loyola University of Chicago.

出版信息

Eur J Nucl Med. 1994 Jun;21(6):590-3.

PMID:8082674
Abstract

Significant changes in the medical environment in the United States pose difficult questions for small medical specialties such as nuclear medicine. How do we get our voice heard in the debates that surround the reform process? What type of information is required to demonstrate the efficacy of nuclear medicine procedures? The older measures of sensitivity and specificity do not carry the same weight in health planning circles as they do in science. Data demonstrating the impact on the outcome for the patient are preferred. American nuclear medicine has started producing outcome data. We have high hopes that we can demonstrate to health planners both the medical and economic benefits of our specialty. Cardiac procedures seem to have an excellent chance of withstanding the challenges of analysis. Some oncologic procedures such as bone imaging are likely to survive unscathed as well. However, where procedure costs are very high, and the gains marginal, such as oncologic antibody imaging, there are serious questions about how these procedures will be reviewed. Likewise, while PET systems still hold great promise, unless data showing a positive impact on medical and economic outcome can be presented, this area is also in jeopardy. Where there is little challenge to the procedure, such as lung scanning, in all likelihood the procedure will retain its current place in the diagnostic algorithm. In closing, clearly as resources become increasingly scarce in medicine, difficult choices must be made. In the past, many of these decisions were made by those with the loudest voices.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

美国医疗环境的重大变化给核医学等小型医学专科带来了难题。在围绕改革进程的辩论中,我们如何让自己的声音被听到?证明核医学程序有效性需要何种类型的信息?传统的敏感性和特异性指标在卫生规划领域的分量,已不如在科学领域那么重。能证明对患者预后有影响的数据更受青睐。美国核医学已开始产出预后数据。我们满怀希望,能向卫生规划者展示我们专科在医学和经济方面的益处。心脏程序似乎极有可能经受住分析的挑战。一些肿瘤学程序,如骨显像,可能也会安然无恙。然而,对于那些成本极高而收益甚微的程序,如肿瘤抗体显像,这些程序将如何接受审查存在严重问题。同样,尽管正电子发射断层扫描(PET)系统仍极具前景,但除非能拿出对医学和经济结果有积极影响的数据,否则这一领域也岌岌可危。对于那些程序几乎没有挑战的情况,如肺部扫描,该程序很可能会在诊断流程中保留其现有地位。总之,显然随着医学资源日益稀缺,必须做出艰难抉择。过去,许多此类决策是由嗓门最大的人做出的。(摘要截选于250词)

相似文献

1
A new approach to the study of diagnostic procedures in the United States.美国诊断程序研究的一种新方法。
Eur J Nucl Med. 1994 Jun;21(6):590-3.
2
Beware the Medical-Industrial Complex.警惕医疗产业联合体。
Oncologist. 1996;1(4):IV-V.
3
Visions and revisions: viewpoints on nuclear medicine & health care reform. Part 1: Outcomes research.
J Nucl Med. 1994 May;35(5):23N-24N, 26N.
4
[Telecommunications, health and radiology: potential synergies for the new millennium].[电信、健康与放射学:新千年的潜在协同作用]
Radiol Med. 2001 Jul-Aug;102(1-2):14-9.
5
Is nuclear medicine cost-effective?核医学是否具有成本效益?
Dimens Health Serv. 1991 Mar;68(2):21-3.
6
Procedures and methods of benefit assessments for medicines in Germany.德国药品效益评估的程序和方法。
Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.
7
Cost-effectiveness of hospice care.临终关怀的成本效益。
Clin Geriatr Med. 1996 May;12(2):417-28.
8
Family pediatrics: report of the Task Force on the Family.家庭儿科学:家庭问题特别工作组报告
Pediatrics. 2003 Jun;111(6 Pt 2):1541-71.
9
[The origin of informed consent].[知情同意的起源]
Acta Otorhinolaryngol Ital. 2005 Oct;25(5):312-27.
10
Surgeons: A Future Role in Clinical Trials?外科医生:在临床试验中未来会扮演何种角色?
Oncologist. 1997;2(3):V-VI.